Sutro Biopharma (STRO) Expected to Post Earnings on Thursday

Sutro Biopharma (NASDAQ:STRO) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Sutro Biopharma to post earnings of ($2.2204) per share and revenue of $11.7760 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

Sutro Biopharma (NASDAQ:STRO) last issued its earnings results on Thursday, May 14th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The firm had revenue of $14.52 million for the quarter, compared to analyst estimates of $8.89 million. On average, analysts expect Sutro Biopharma to post $-9 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Sutro Biopharma Price Performance

NASDAQ:STRO traded up $0.37 during mid-day trading on Tuesday, reaching $25.47. The stock had a trading volume of 10,159 shares, compared to its average volume of 252,541. The company has a market capitalization of $421.97 million, a price-to-earnings ratio of -2.32 and a beta of 1.55. Sutro Biopharma has a 1-year low of $7.15 and a 1-year high of $43.85. The stock’s 50 day simple moving average is $27.60 and its two-hundred day simple moving average is $25.44.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on STRO. Weiss Ratings reissued a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Friday, May 8th. Leerink Partners set a $43.00 target price on shares of Sutro Biopharma and gave the company an “outperform” rating in a research note on Friday, May 15th. Truist Financial assumed coverage on shares of Sutro Biopharma in a report on Thursday, June 11th. They set a “buy” rating and a $50.00 target price on the stock. Barclays started coverage on shares of Sutro Biopharma in a research report on Thursday, May 28th. They set an “overweight” rating and a $56.00 price objective for the company. Finally, Citizens Jmp raised their target price on shares of Sutro Biopharma from $35.00 to $41.00 and gave the stock a “market outperform” rating in a report on Thursday, April 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.44.

Institutional Trading of Sutro Biopharma

Hedge funds have recently bought and sold shares of the company. State of Tennessee Department of Treasury acquired a new position in Sutro Biopharma in the fourth quarter worth approximately $86,000. Jane Street Group LLC acquired a new stake in shares of Sutro Biopharma during the 4th quarter valued at $265,000. Bridgeway Capital Management LLC lifted its position in shares of Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after acquiring an additional 30,000 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Sutro Biopharma by 51.3% during the 3rd quarter. Bank of America Corp DE now owns 119,434 shares of the company’s stock worth $104,000 after acquiring an additional 40,488 shares in the last quarter. Finally, Shay Capital LLC boosted its stake in shares of Sutro Biopharma by 20.1% during the 3rd quarter. Shay Capital LLC now owns 312,051 shares of the company’s stock worth $271,000 after acquiring an additional 52,162 shares in the last quarter. 96.99% of the stock is currently owned by institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.